European Conference

Friday, December 11, 1998
8.30 - 8.45 INTRODUCTIONS AND CONFERENCE OBJECTIVES - DAY TWO
Peter G. Davey MD, FRCP, MEMO, University of Dundee, ISPOR Conference Co-chair
Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Conference Co-chair
Jonathan Cooke MPharm, PhD, South Manchester University Hospitals, ISPOR Conference Co-chair
Alan L. Hillman MD, MBA, University of Pennsylvania, ISPOR Conference Co-chair
8.45 - 10.15 PLENARY SESSION
8.45 - 9.30What Is the Current Use and Future Trends for Pharmacoeconomic and Outcomes Information in European Countries
presented by: Michael Drummond PhD, Professor, Centre for Health Economics, University of York
8.45 - 9.30World Health Organization (who) Health Policy Concept in Europe
presented by: Herbert F.K. Zöllner PhD, Regional Adviser, WHO Health Economics and Policy Analysis, Copenhagen, Denmark
10.15 - 10.30 BREAK
10.30 - 12.30 FIRST GENERAL SESSION
 Developing Consensus on Pharmaoeconomic Methodology
Moderator: Peter Davey MD, FRCP, MEMO, University of Dundee, Dundee, Scotland
REPORT FROM THE ISPOR US CONSENSUS DEVELOPMENT ADVISORY PANELS ON THE STANDARDIZATION OF PHARMACAECONOMIC METHODOLOGY
Speaker: Joel W. Hay PhD, University of Southern California, College of Pharmacy, Los Angeles, CA, USA
DEVELOPING CONCENSUS ON PHARMACOECONOMIC METHODOLOGY - COMPARING AND CONTRASTING THE HARMET AND OTHER INITIATIVES IN EUROPE TO THE US INITIATIVE - STRENGTHS AND WEAKNESSES
Speakers: The European Panel
  • Werner Brouwer MD, The Netherlands
  • Jonathan Cooke MPharm, PhD, MPharm, South Manchester University Hospitals, Manchester, UK
  • Michael Drummond PhD, University of York, Centre for Health Economics, York, UK
  • Livio Garattini MD, CESAV Centre for Health Economics, Institute for Pharmacological Research, Ranica, Italy
  • Bengt G. Jönsson MA, PhD, Stockholm School of Economics, Stockholm, Sweden (invited)
  • Karl W. Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany
  • Frank Peys PhD, Belgium Institute for Health Economics, Brussels, Belgium
  • Claude Le Pen PhD, Université Paris-Dauphine, Paris, France
  • Hugo Robays, University Hospital Gent, Gent, Belgium
  • Joan Rovira PhD, SOIKOS, Department of Economics, University of Barcelona, Barcelona, Spain
  • J.Matthias Graf von Schulenberg PhD, Centre for Health Economics and Health System-HSR, University of Hannover, Hannover, Germany
12.30 - 13.30 LUNCH & CONTRIBUTED POSTER PRESENTATIONS - SESSION 1
13.30 - 15.00 SECOND GENERAL SESSION
 Using Evidence-Based Medicine to Deliver Cost-Effective Health Care - Focusing on Cardiovascular Disease
Moderator: Alan L. Hillman MD, MBA University of Pennsylvania, School of Medicine, Philadelphia, PA USA
COST-EFFECTIVE MANAGEMENT OF HYPERTENSION
Speaker: Hanne Thümer, Regional Hospital of Trondheim, Trondheim, Norway
CONTROVERSIES WITH LIPID-LOWERING AGENTS
Speaker: Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany
WHY DON'T DOCTORS PRESCRIBE EFFECTIVE TREATMENTS FOR SECONDARY PREVENTION AFTER ACUTE MYOCARDIAL INFARCTION?
Speaker: David Wood MD, ChB, MSc, FRCP, FESC, Imperial College School of Medicine at the National Heart and Lung Institute, Royal Brompton NHS Trust and Bromley Hospital NHS Trust, London, UK
15.00 - 15.30 BREAK AND VIEWING OF CONTRIBUTED POSTER PRESENTATIONS - SESSION 2
15.30 - 17.30 CONTRIBUTED PODIUM PRESENTATIONS - ORIGINAL RESEARCH
 Economic & Outcomes Study Results for Cardiovascular Disease
15.30 - 15.50 CV1 ECONOMIC IMPACT OF THE ANTI-HYPERTENSIVE THERAPY WITH VALSARTAN
Fricke F-U, Pirk O, Novartis Pharma GmbH, Department of Health Economics, Nuremberg, Germany
15.50 - 16.10 CV2 COST-EFFECTIVENESS OF TREATING HIGH RISK INDIVIDUALS AGE 45-65 WITH STATINS IN GERMANY FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE
Lauterbach K, Hunsche E, Klewer U, Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany
16.10 - 16.30 CV3 UTILIZATION OF ACE INHIBITORS IN CONGESTIVE HEART FAILURE AMONG ELDERLY IN QUEBEC
Couture J, Blais L, Castilloux A-M, LeLorier J. Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada
16.30 - 16.50 CV4 IMPROVED MYOCARDIAL PROTECTION DURING CORONARY BYPASS SURGERY SHORTENS HOSPITAL STAY AND SAVES COSTS
Mehlhorn U, Fattah M, Kuhn-Regnier F, Geissler HJ, Südkamp M, Horst M, Hekmat K, Dapunt O, de Vivie ER, Clinic for Cardiothoracic Surgery, University of Cologne, Cologne, Germany
16.50 - 17.10 CV5 ECONOMIC ASSESSMENT OF A PROPHYLACTIC TREATMENT OF RECURRENCE OF ISCHEMIC ACCIDENTS BY LYSINE ACETYLSALICYLATE
Marissal JP, Selke B, Lebrun T, CRESGE, Lille, France
17.10 - 17.30 CV6 OUTCOME OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH A MAXIMAL INDIVIDUAL THERAPIE (MITRA-STUDY)
Dommke C, Schiele R, Fischer F, Wienbergen H, Voigtländer T, Glunz HG, Berg G, Gieseler U, Lauterbach KW1, Senges J. Herzzentrum Ludwigshafen; Universität Köln, for the MITRA Study Group, Köln, Germany
15.30 - 17.30 CONTRIBUTED PODIUM PRESENTATIONS - ORIGINAL RESEARCH
 Economic & Outcomes Study Results for Mental Health
15.30 - 15.50 MH1 ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED WITH BENZODIAZEPINE USE
Barbone F2, McMahon AD1, Davey PG1, Morris AD, McDevitt DG, MacDonald TM1, 1Medicines Monitoring Unit (MEMO), University of Dundee, Ninewells Hospital & Medical School, Dundee, Scotland, 2Chair of Hygiene and Epidemiology, DPMSC, University of Udine, Italy
15.50 - 16.10 MH2 NEW BENZODIAZEPINE USE IS ASSOCIATED WITH AN AGE RELATED RISK OF HOSPITALISATION WITH FRACTURE AND OTHER TRAUMA: A POPULATION BASED STUDY
Steinke D1, Davey P1, Elliott L2, Dowell J3, Morris A1, MacDonald T1, 1Medicines Monitoring Unit; 2Tayside School of Nursing & Midwifery; 3Tayside Centre for General Practice, Ninewells Hospital, Dundee, Scotland
16.10 - 16.30 MH3 ASSESSING THE SASKATCHEWAN DATABASE FOR OUTCOMES STUDIES OF DEPRESSION AND ITS TREATMENT
West S, Richter A, Nennstiel M, Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA
16.30 - 16.50 MH4 ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIOURS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY, IN FRANCE; 1. EPIDEMIOLOGY
Cal M-L1, Dartigues J-F2, Gérard D3, Léger J-M4, 1Groupe de Recherche en Économie de la Santé, Université Victor Segalen, Bordeaux, France; 2INSERM U330, Université Victor Segalen, Bordeaux, France; 3Laboratoires Synthélabo, Meudon-La-Forêt, France; 4Centre Hospitalier Spécialisé Esquirol, Limoges, France
16.50 - 17.10 MH5 ECONOMIC IMPACT OF AGITATED AND AGRESSIVE BEHAVIOURS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY, IN FRANCE: 2. COST ANALYSIS
Cal M-L1, Prudhomme M-L2, 1Groupe de Recherche en Économie de la Santé, Université Victor Segalen Bordeaux2, France; 2Synthélabo, Meudon-La-Forêt, France
17.10 - 17.30 MH6 COST-UTILITY ANALYSIS OF RISPERIDONE IN CHRONIC SCHIZOPHRENIA
Iskedjian M, Oh P, Einarson TR, Lanctût K, Addis A. University of Toronto, Toronto, Canada
15.30 - 17.30 CONTRIBUTED PODIUM PRESENTATIONS - ORIGINAL RESEARCH
 Economic & Outcomes Study Results for Diabetes and Infectious Disease
15.30 - 15.50 D1 SELF-MONITORING OF BLOOD GLUCOSE IN DIABETES: IS IT WORTH IT?
Evans JMM, Boyle DIR, Davey PG, Morris AD; The DARTS / MEMO Collaboration, University of Dundee, Dundee, Scotland
15.50 - 16.10 D2 PATIENT-HELD INSTRUMENTS FOR RECORDING AMBULATORY CARE RESOURCE USE: EXPERIENCE IN PATIENTS WITH DIABETIC FOOT ULCERS
Constenla D1, Chambers M1, Sigler C2, 1MEDTAP International Inc., London, UK; 2Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA
16.10 - 16.30 D3 ANTITHYROID DRUGS OR RADIOIODINE AS FIRST-LINE THERAPY OF GRAVES' HYPERTHYROIDISM IN A COUNTRY WITH STRICT REGULATIONS FOR RADIATION PROTECTION ?
Dietlein M1, Moka D1, Hunsche E2, Dederichs B1, Lauterbach KW2, Schicha H1, 1Department of Nuclear Medicine; 2Institute of Health Economics, University of Cologne, Cologne, Germany
16.30 - 16.50 D4 MEASURING THE IMPACT OF DIABETIC FOOT ULCERS ON QUALITY OF LIFE FROM THE PATIENT'S PERSPECTIVE
J Ward1 P McNulty2, L Abetz3, M Sutton1, and L Brady2, 1Johnson & Johnson, USA; 2Royal Hallamshire Hospital, Cheshire, UK, 3Mapi Values, Cheshire, UK
16.50 - 17.10 IM1 ASSESSING THE VALUE OF EPOETIN ALFA VS. AUTOLOGOUS BLOOD DONATION IN ORTHOPEDIC SURGERY: A FEASIBILITY STUDY OF CONTINGENT VALUATION
Persson U,1Martens L2, 1IHE, Swedish Institute for Health Economics, Lund, Sweden; 2ICOM Health Economics, Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
17.10 - 17.30 IM2 EPOETIN ALFA REDUCES POST-OPERATIVE LENGTH OF STAY IN PATIENTS UNDERGOING KNEE REPLACEMENT
Gagnon D, Parasuraman B, Martens L, ICOM Health Economics, Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
17.30 - 18.30 KEYNOTE SPEAKERS & COMMITTEE RECOGNITION
 Keynote Speakers:
Professor Erland Erdmann MD, Prorektor of the University of Cologne
Robert S. Epstein MD, MS, Vice President, Merck-Medco Managed Care LLC, Montvale, NJ, USA and ISPOR President

18.30 - 20.00 RECEPTION AND VIEWING OF CONTRIBUTED POSTER PRESENTATIONS - SESSION 2
 Contributed Poster Presentations
 INFECTIOUS DISEASE
 PID1 COST EFFECTIVENESS OF LEVOFLOXACIN VERSUS CLARITHROMYCIN IN PATIENTS EVALUABLE FOR CLINICAL EFFICACY IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
Rance L F1, Dornsief B F2, 1Janssen-Ortho Inc., Toronto, Canada; 2Advanced Biologics, Lambertville, NJ USA
 PID2 COST-MINIMIZATION ANALYSIS OF CEFAMANDOLE AND TOBRAMYCIN VS STANDARD THERAPY IN THE TREATMENT OF PATIENTS WITH LOCAL APPENDICULAR PERITONITIS
Rozenson O1, Bazganov N2, Belkov A1, Bikov A3, Stratchounski L1, 1Smolensk State Medical Academy, Smolensk, Russia; 2Yaroslavlskya State Medical Academy, Yaroslavl, Russia; 3Volgogradskaya State Medical Academy, Volgograd, Russia
 MENTAL HEALTH AND NEUROLOGIC DISORDERS
 PMH1 ANNUAL DIRECT COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS IN INDIA
Chaturvedi, Santosh K, National Institute of Mental Health & Neurosciences, Bangalore, India
 PMH2 CLINICAL AND ECONOMIC CHARACTERIZATION OF FAMILY MEDICINE PATIENTS RECEIVING ANTIDEPRESSANT DRUGS
Taylor AT1, Wagner PJ2, Ahmed A1, 1University of Georgia College of Pharmacy and 2Medical College of Georgia School of Medicine, Athens and Augusta, GA, USA
 PMH3 COST-EFFECTIVENESS OF FLUVOXAMINE IN THE TREATMENT OF RECURRENT DEPRESSION IN FRANCE
Nuijten MJC1, Piercy J2, 1The Lewin Group, Hoofddorp, The Netherlands; 2Solvay Pharmaceuticals, Hannover, Germany
 PMH4 THE BUDGET IMPACT PHARMACOTHERAPY SELECTION FOR MAJOR DEPRESSIVE DISORDER: A MULITNATIONAL STUDY
Casciano, JP1, Einarson, TR3, Arikian, SA1,2, Doyle, JJ1,2,1The Analytica Group, Ltd., New York, NY, USA; 2Columbia School of Public Health, New York, NY, USA; 3Faculty of Pharmacy, University of Toronto, Ontario, Canada
 PMH5 COST OF CARE OF ALZHEIMER'S DISEASE IN THE UNITED KINGDOM
Thwaites RMA1, Yeardley HL2, 1Glaxo Wellcome Research & Development, Greenford, UK; 2Quintiles, Neu-Isenburg, Germany
 PMH6 DEVELOPMENT OF A NEW DISEASE-SPECIFIC QUALITY OF LIFE SCALE FOR USE IN SCHIZOPHRENIA
Wild D1, Jenkinson C1, Fitzpatrick, R1, Wilkinson G2, Hesdon, B2, Farina C3, 1Oxford Outcomes, Institute of Health Sciences, Oxford, UK; 2Department of Psychiatry, University of Liverpool, Liverpool, UK; 3Janssen Cilag Ltd, Saunderton, High Wycombe, UK
 PMH7 CROSS-CULTURAL ADAPTATION OF THE INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) IN 31 COUNTRIES
Conway K1, Mishra A2, Giroudet C1, The Global Translation Group (31 QoL Experts) 1Mapi Research Institute, Lyon, France; 2Pfizer, Groton, CT, USA
 PN1 A UK PRIMARY CARE DATABASE (UKPCD)-UK MEDIPLUS AS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE INCIDENCE AND PREVALENCE OF MULTIPLE SCLEROSIS, ITS TREATMENT, PRESCRIPTION COSTS AND REFERRALS IN UK PRACTICE
Carmichael R, Grigas E, Harrison P, McDermott, J, Disease Treatment and Outcomes Group, IMS Health, Middlesex, England
 PN2 RESULTS OF DISEASE MANAGEMENT IN HEADACHE TREATMENT
Göbel H1, Behrens M2, 1Neurological Clinic, University of Kiel and Neurological Pain Clinic, Kiel, Germany; 2Glaxo Wellcome GmbH&Co., Hamburg, Germany
 PN3 A FOUNDATION STUDY FOR COST-EFFECTIVENESS ANALYSIS: THE DEFINITION OF ECONOMIC PARAMETERS AND CLINICAL ENDPOINTS IN PARKINSON'S DISEASE
Saal G1, Adesina K1, Shuster S2, 1MAPI Values, Cheshire, UK; 2Medtronic Neurological, Minneapolis, MN, USA
 PN4 QUALITY OF LIFE AND FUNCTIONAL STATUS MEASURES IN ADVANCED PARKINSON'S PATIENTS TREATED WITH PRAMIPEXOLE, BROMOCRIPTINE, OR PLACEBO
Greer M1, Guttman M2, Meier D3, Leonard J3, Koester J3; 1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Markham, Ontario, Canada; 3Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany
 PN5 CROSS-CULTURAL ADAPTATION OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS) QUESTIONNAIRE IN 9 COUNTRIES
Conway K1, Ojanen M1, Cella D2, Lent L2, Eremenco S2, Sagnier P3, 1Mapi Research Institute, Lyon, France; 2Center on Outcomes, Research and Education, Evanston, IL, USA; 3Bayer AG, Pharma Europe, Leverkusen, Germany
 PULMONARY AND ARTHRITIC DISORDERS
 PP1 CHARACTERISTICS OF CHRONIC AIRWAY DISEASE PATIENTS STARTED ON NEBULIZED IPRATROPIUM SOLUTION
Blais L1, Castilloux A-M1, Renzi P1, LeLorier J1, Miller B2. 1Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Canada, 2Boehringer Ingelheim Ltd, Burlington, Ontario, Canada
 PP2 THE EFFECT OF AGE ON COST-EFFECTIVENESS IN THE TREATMENT OF MODERATE ASTHMA
Kielhorn, A, Behrens, M, Glaxo Wellcome GmbH&Co, Hamburg, Germany
 PP3 INCREMENTAL COST OF DISEASE IN NOSOCOMIAL PNEUMONIA FROM A HOSPITAL'S PERSPECTIVE - A FEASIBILITY STUDY
Dietrich ES1, Hug S1, Mast O2, Schulgen G3, Daschner F1, 1Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany; 2Health Economics and Outcomes Research, Bayer Vital, Leverkusen, Germany; 3Institute of Biometry and Medical Informatics, University Hospital, Freiburg, Germany
 PP4 ECONOMIC IMPACT OF SMOKING IN GERMANY
Ruff L1, Meyer A1, Volmer T2, Nowak D3 1Medizinische Klinik, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany; 2Glaxo Wellcome, Hamburg, Germany; 3Institut und Poliklinik für Arbeits-und Umweltmedizin, Ludwig Maximilians-Universität, München, Germany
 PIM1 COST-EFFECTIVENESS ANALYSIS OF A FIXED COMBINATION DICLOFENAC+MISOPROSTOL IN THE PREVENTION OF GASTROPATHY IN ARTHRITIS PATIENTS IN BELGIUM
Annemans L, Vanoverbeke N, Van Rompay W, HEDM, Mechelen, Belgium
 PIM2 COST OF ILLNESS IN EARLY RHEUMATOID ARTHRITIS STRATIFIED FOR SOCIAL STATUS
Merkesdal S, Ruof J, Mau W, Zeidler H, Department of Rheumatology, Medical School of Hannover, Hannover, Germany
 PIM3 QUALITY OF LIFE SCORES AS PREDICTORS OF FUTURE HEALTHCARE RESOURCE USE IN PATIENTS WITH ARTHRITIS
Wolfe F1, Kahler K2, Kong SX2, 1Arthritis Research Center, University of Kansas, Wichita, KS, USA; 2Merck & Co., Inc., Whitehouse Station, NJ, USA
 PHARMACOECONOMIC METHODS AND COST OF CARE
 PMC1 MEDICATION COMPLIANCE AND EXPENDITURE IMPACT ASSOCIATED WITH PHARMACIST'S COGNITIVE SERVICE INTERVENTIONS
Smith D1,2, Stergachis A1, Christensen D1,3, Sullivan S1, 1School of Pharmacy, University of Washington, Seattle, WA, USA; 2Centre for Health Economics, University of York, York, England; 3School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
 PMC2 RUNNING COST OF TREATING A PATIENT IN A GENERAL MEDICAL WARD IN SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN
Al-Zakwani I, Rao S, Al-Riyamy K, Balkhair A, Sultan Qaboos University Hospital, Muscat, Oman
 PMC3 SURVIVAL GAINS AND DEGREE OF THERAPEUTIC INNOVATION
Messori A, Trippoli S, Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy
 PMC4 LINKING HRQOLS TO LARGE NATIONAL DATA SETS: EUROQOL AND HUI INDICES PRIVATE
Rizzo JA, Sindelar JL1, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA
 PMC5 USING A SURROGATE SAMPLE TO DERIVE PATIENT PREFERENCES FOR A COST-UTILITY ANALYSES IN A RAMDOMIZED CLINICAL TRIAL
Lustig S1, Lispcomb J2, Salsburg D3, Trost C1, Turner R5, 1Pfizer, Groton, CT, USA, 2Duke University, Durham, NC, USA, 3New London, CT, USA, 4Phase V Technologies, Inc., Wellesley Hills, MA, USA
 PMC6 ADVANCED SENSITIVITY ANALYSIS BY THE INTEGRATION OF POINT-SENSITIVITY AND RANGE-SENSITIVITY USING PROBABILITY DISTRIBUTIONS
Mark J.C. Nuijten, The Lewin Group, Hoofddorp, The Netherlands

European Conference Main Page